Ally Bridge MedAlpha Master Fund L.P. 13D and 13G filings for Syros Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-02-11 4:17 pm Purchase | 2021-12-31 | 13G | Syros Pharmaceuticals, Inc. SYRS | Ally Bridge MedAlpha Master Fund L.P. | 393,052 6.300% | 89,740 (+29.59%) | Filing |
| 2020-12-18 4:20 pm Purchase | 2020-12-08 | 13G | Syros Pharmaceuticals, Inc. SYRS | Ally Bridge MedAlpha Master Fund L.P. | 303,313 5.400% | 303,313 (New Position) | Filing |